Oniria Therapeutics receives €100,000 Startup Capital grant from Government of Catalonia

Oniria Therapeutics has been awarded a €100,000 Startup Capital grant from ACCIÓ, the Government of Catalonia agency for business competitiveness, to promote growth in early stage tech start-ups, helping them develop their product and validate their business model to reach the market.

Startup Capital is a call for competitive non-refundable grants with €2 million earmarked to award in 2022 to companies younger than 18 months. The call received more than a hundred applications from start-ups.

Specifically, Oniria Therapeutics will allocate this grant to the EpiGold-G: Development of a biosensor in liquid biopsy to detect epigenetic modifications project, with the aim of developing a selection and companion diagnostic biomarker that could potentially be used in future clinical trials with the company’s flagship product ONR-001 .

Created in 2021, Oniria Therapeutics is a biopharmaceutical spin-off of the Vall d’Hebron Institute of Oncology (VHIO), University of Barcelona (UB), and the Catalan Institution for Research and Advanced Studies (ICREA) that is developing innovative drugs for precision oncology to eliminate persistent tumour cells. The most advanced of their projects is ONR-001, a first-in-class and patented drug in the preclinical phase that modulates the TET2 epigenetic factor.